Goldman Sachs
SMMT icon

Goldman Sachs’s Summit Therapeutics SMMT Stock Holding History

Goldman Sachs’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,100
Closed -$832K – 6630
2025
Q2 		$832K Hold
39,100
– – ﹤0.01% 4827
2025
Q1 		$754K Buy
+39,100
New +$784K ﹤0.01% 4912
2024
Q4 		– Sell
-36,400
Closed -$797K – 6246
2024
Q3 		$797K Buy
+36,400
New +$509K ﹤0.01% 4791

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's SMMT Position: Q2 2026 in Review

Goldman Sachs increased its Summit Therapeutics (SMMT) stake by 1,353% in Q2 2026, buying an estimated $74.5M and bringing the position to 4,513,399 shares worth $65.8M. The position accounts for 0.01% of the portfolio, ranked #1572.

Goldman Sachs first reported a position in SMMT in Q4 2020 and has held it in 23 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Goldman Sachs held 4,513,399 shares of Summit Therapeutics worth $65.8M as of Q2 2026.
  • Goldman Sachs bought 4,202,671 Summit Therapeutics shares in Q2 2026, an estimated $74.5M.
  • Summit Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1572 holding.
  • Goldman Sachs first reported a position in Summit Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.